Targeting cGAS–STING in Kidney Fibrosis: Macrophages’ Dual Role Is Key
Background: Macrophages link inflammation and tissue repair
Strategies to inhibit the cGAS–STING pathway in kidney fibrosis must account for macrophages’ role in promoting fibrosis as well as inflammation. A review published in Frontiers in Immunology summarizes the relationship between this pathway and macrophages and examines its potential and limitations as a therapeutic target. It does not report results from a new clinical trial; evidence supporting therapeutic effects comes mainly from animal studies.
In chronic kidney disease (CKD), persistent inflammation and excessive accumulation of extracellular matrix (ECM) lead to structural kidney damage and declining function. ECM refers to materials such as collagen that support the area around cells. It helps repair tissue after injury, but continued accumulation leads to fibrosis.
Macrophages contribute to both inflammation and repair. The review describes the distinct effects of a pro-inflammatory state during acute injury and a repair-associated state during recovery. It is difficult to conclude that shifting macrophages toward a less inflammatory state alone will also suppress fibrosis.
Key findings: The effects of targeting this pathway cannot be explained by a shift to M2 alone
Cyclic GMP–AMP synthase (cGAS) and stimulator of interferon genes (STING) form an innate immune signaling pathway that begins with the detection of cytosolic DNA. According to the review, mitochondrial DNA and other material released from damaged renal tubular epithelial cells can activate this pathway. Subsequent inflammatory signaling is amplified, affecting macrophage states and matrix accumulation.
During acute injury, the inflammatory M1 state worsens tissue damage, whereas the M2 state during recovery helps tissue repair and resolution of inflammation. However, in a chronic fibrotic environment, sustained M2-associated activity can promote fibroblast activation and ECM accumulation alongside signals such as transforming growth factor beta (TGF-β). The review’s authors emphasize that actual macrophage states do not fall into two fixed M1 and M2 categories, but instead span a continuum.
Potential targets are not limited to STING. In a mouse unilateral ureteral obstruction (UUO) model described in the review, daily administration of the cGAS inhibitor RU.521 at 10 mg per kg of body weight reduced levels of inflammatory factors and the proteins fibronectin, type I collagen, and alpha-smooth muscle actin (α-SMA) in kidney tissue. This is a preclinical result cited by the review; it does not establish a dose or efficacy for humans. The review’s account alone does not allow verification of the experiment’s sample size, treatment duration, or effect size.
The STING inhibitor H-151 is also discussed. The review reports that H-151 treatment reduced macrophage-to-myofibroblast transition and ECM accumulation in a folic acid–induced kidney fibrosis model. H-151 inhibits STING and affects downstream signaling, distinguishing it from RU.521, which targets cGAS.
Implications and outlook: Efficacy and immune safety need to be evaluated together
The review highlights the difficulty of describing cGAS–STING inhibition simply as a strategy to shift macrophages from M1 to M2. The possibility that outcomes vary depending on which cells are targeted and at what disease stage needs to be considered. The authors propose follow-up studies using single-cell and spatial transcriptomic analyses to examine macrophage subtypes and their interactions with nearby cells.
Delivery technologies and gene-regulation approaches remain at the preclinical exploration stage. The material provided offers no clinical evidence supporting the conclusion that a drug reaches only injured kidneys or substantially reduces systemic side effects. Because this pathway also contributes to antiviral defense and tumor immunity, potential risks of long-term inhibition must also be assessed. Whether these approaches reduce the progression of kidney failure or the need for dialysis requires further clinical validation.
Sources: Full review, Bibliographic record and abstract.
Renal fibrosis, a pivotal pathological hallmark of chronic kidney disease (CKD), arises from persistent inflammatory responses and extracellular matrix (ECM) deposition. Emerging evidence indicates the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway exerts a crucial influence on the progression of renal fibrosis. This pathway exacerbates the release of inflammatory factors and ECM deposition through reprogramming the polarization state of macrophages, thereby driving renal fibrosis. This review delineates the regulatory role of the cGAS-STING signaling pathway in macrophage-related renal fibrosis and critically evaluates emerging innovative strategies targeting this pathway, including small molecule inhibitors, nanocarrier-based delivery systems, and gene editing technologies. However, current research still faces certain limitations, including the complexity of molecular mechanisms, differences in research results, and challenges in clinical translation. By synthesizing recent advances in cGAS-STING-mediated macrophage reprogramming for renal fibrosis intervention, this review aims to provide a foundation for precise therapeutic development.
The review shows why a reduction in inflammatory factors alone is insufficient to judge an antifibrotic effect when developing treatment candidates for kidney fibrosis. For example, a preclinical study evaluating a cGAS or STING inhibitor could distinguish acute injury from chronic fibrosis and assess macrophage-state changes alongside collagen and ECM accumulation. An increase in M2-associated markers should not, by itself, be interpreted as a beneficial response. Local delivery strategies also need to be evaluated for whether they reach their targets within the kidney and how they affect systemic immune function. These are implications for candidate evaluation and follow-up study design; the findings do not establish a treatment recommendation for current patients or demonstrate a reduction in the need for dialysis.